Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb/ImaRx Pharmaceutical

This article was originally published in The Gray Sheet

Executive Summary

Firms enter into licensing agreement whereby Bristol-Myers acquires manufacturing and marketing rights to SonoRx, an orally administered ultrasound contrast agent developed by ImaRx. According to Bristol-Myers, "SonoRx may allow physicians to see . . . internal organs more easily by eliminating the gas artifacts that can prevent clear delineation of structures" during abdominal ultrasound procedures. The firm says it intends to submit an investigational new drug application for SonoRx in 1993 and complete clinical trials during 1994. It adds that its subsidiary Westwood Squibb of Buffalo, New York will manufacture the agent.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel